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1. Introduction
Amyloidosis is a disease characterized by deposition of extracellular proteinaceous mate‐
rial  known  as  amyloid  in  tissues.  Amyloidoses  are  classified  according  to  the  protein
composition and the clinical characteristics of the disease [1].  Amyloid protein can accu‐
mulate at various speeds in multiple organ systems and the disease can have localized or
systemic  manifestations  depending  on  organ involvement.  Amyloidotic  cardiomyopathy
or cardiac amyloidosis is characterized as a restrictive cardiomyopathy associated with in‐
creased  ventricular  wall  thickness  caused  by  the  accumulation  of  amyloid  in  the  heart
[2].Cardiac amyloidosis is of special interest since its occurrence usually has a significant
impact on morbidity and prognosis.
1.2. Subtypes of amyloid disease with cardiac manifestations
At least 27 different precursor proteins for amyloidosis have been identified [3]. Although
almost every amyloidogenic protein can deposit in the heart, a few specific types of amyloid
have a predilection to involve this organ and are responsible for most clinical presentations.
Of the nine proteins that have been shown to potentially involve the heart, two proteins: the
immunoglobulin light chain and the serum protein transthyretin are responsible for the two
clinically most important types of cardiac amyloidosis. Immunoglobulin light chain is
involved in AL amyloidosis and transthyretin (TTR) is involved in both familial- ATTR and
senile-SSA amyloid types. Other rare amyloid types that involve the heart (such as apolipo‐
protein A1) and amyloid types unusual to involve the heart such as secondary amyloid (AA)
[4] or hemodialysis associated (Aβ2M) will not be discussed in this chapter. Another more
recently described type of cardiac amyloidosis results in isolated atrial deposition. Deposited
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atrial amyloid resembling natriuretic peptides [5] was initially thought to be of questionable
clinical significance. This subtype, found mostly in elderly women, is increasingly associated
with atrial fibrillation [6],[7] and remodeling [8] but tends not to be associated with the classical
clinical findings of cardiac amyloidosis.
1.3. Light chain (AL) Amyloidosis
This is the most common systemic amyloidosis in the United States and the most common
cause of cardiac amyloidosis. It occurs equally in men and women usually over the age of 50.
The incidence of AL in the United States is between 2000 and 2500 cases a year [9],[10]. This is
a systemic disease most commonly involving more than one organ system which may include
the kidneys, liver, nerves, and blood vessels. Therefore, most patients have clinical evidence
of extra cardiac involvement including proteinuria, peripheral and autonomic neuropathy and
evidence of liver and skin involvement. Periorbital purpura is a relatively rare, but character‐
istic finding. Amyloid can be detected in the heart in almost every case but clinical cardiac
involvement is encountered in about half of cases. However, when present, cardiac amyloi‐
dosis will usually dominate the clinical presentation and has the greatest impact on survival
[11]. The amyloid is derived from monoclonal light chains (intact or fragmented) produced
from a population of clonal plasma cells. It is generally thought that organ dysfunction in AL
is primarily due to infiltration by the amyloid deposits, but there is increasing evidence for a
direct toxic effect of the amyloidogenic light chain [12],[13]. To support this paradigm, after
successful chemotherapy patients with AL amyloidosis frequently have improvement in heart
failure symptoms associated with decrease in biomarkers despite unchanged echocardio‐
graphic findings [14].
There is  little  overlap with the most  common plasma cell  dyscrasia-  multiple  myeloma.
Only 10-15% of myeloma patients also develop AL amyloidosis and most AL patients do
not develop overt myeloma [9]. These two diseases, however, share several features, that
is, excess bone marrow plasma cells and increased monoclonal proteins in the blood and
urine. Light chain deposition disease of the heart is a rare condition to be differentiated
from AL cardiomyopathy in which cardiac dysfunction may occur due to deposition of
immune light chains that do not form amyloid in the myocardium [15],[16].  This condi‐
tion is related to plasma cell dyscrasias such as multiple myeloma or Waldenstrom’s mac‐
roglobulinemia and like AL amyloidosis may improve after chemotherapy directed at the
underlying bone marrow clone is administered [17].
1.4. Transthyretin amyloidosis
Transthyretin (TTR) is a hepatically synthesized plasma protein. The gene is coded on
chromosome 18 and includes 4 exons. In the serum the protein circulates as a homotetramer,
in which each monomer is comprised of 127 amino acids arranged as 8 antiparallel beta pleated
sheet domains [18]. This structure is prone to form beta pleated sheet fibrils, the building blocks
for amyloid deposition [19]. Transthyretin can accumulate in the heart to cause cardiac
amyloidosis in two clinical syndromes: familial amyloidosis (ATTR) or senile amyloidosis
(SSA), the latter of which is more recently been called age-related amyloidosis.
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1.5. Familial amyloidosis (ATTR)
This disease is most commonly due to a mutation in the TTR protein, and is transmitted as an
autosomal dominant trait. To date, about 100 different amyloidogenic TTR point mutations
have been described [20]. The prevalence and severity of cardiac disease varies with different
mutations. Penetrance may vary resulting in some individuals with a mutated genotype that
may not develop clinical disease. Males and females are equally affected. Interestingly the
cardiac amyloid deposits consist of both wild type as well as mutant TTR [21]. The disease
frequently affects the heart and/or the nervous system. Other manifestations include ocular
involvement with opacities of the vitreous humor [18]. A “scalloped pupil” is pathognomonic
to the disease but is rarely encountered [22]. Carpal tunnel syndrome is another common
feature [18]. Nervous system involvement occurs as a polyneuropathy that usually starts with
paresthesias and dysesthesias in the lower extremities and ascends centripetally [23], with
possible later motor dysfunction. Autonomic nervous system involvement is common,
including dyshidrosis, bowl irregularities, orthostasis, erectile dysfunction, and urinary
retention or incontinence. Although the CNS is usually not involved, certain rare mutations
are associated with leptomeningeal amyloidosis. In contrast to AL amyloidosis, renal involve‐
ment is unusual in TTR associated amyloidosis and neither is liver deposition or macroglossia
a prominent feature. Patients may present with neuropathy, cardiomyopathy or a combination
of both and specific TTR mutations usually determine the organs of primary involvement [24].
Several common mutations warrant specific consideration. Isoleucine to valine substitution at
position 122 (Val122Ile) is among the most common, present in 4% of African Americans [25].
These patients present with severe cardiomyopathy usually by age 60, with little or no
neuropathy [26]. Valine to Methionine substitution at position 30 (Val30Met) is probably the
most studied TTR mutation worldwide. It is prevalent in a few specific locations (also termed
endemic) in Japan [27], Portugal [28] and northern Sweden [29]. In Japan and Portugal patients
usually manifest with neuropathy in the mid 30s, and cardiomyopathy is rare, typically
occurring after the sixth decade. By contrast the same mutation in Sweden usually manifests
later (mid 50s), and has slower progression and lower penetrance [30]. The threonine to alanine
substitution at position 60 (Thr60Ala) usually manifests with predominantly cardiac amyloi‐
dosis and minimal neuropathy.
1.6. Senile amyloidosis (SSA) or age related amyloidosis
This is a non-hereditary form of transthyretin related amyloidosis. It is almost exclusively a
disease of the elderly (>70 years old) and occurs more commonly in men. The disease involves
deposition of amyloid from normal unmutated transthyretin (wild type). Wild type trans‐
thyretin deposits almost exclusively in the heart and when extensive enough is associated with
cardiac disease. The only other manifestation may be carpal tunnel syndrome often preceding
heart failure by 3-5 years. The finding of some transthyretin amyloid deposition is common in
the elderly (up to 25% of autopsies in subjects over the age of 80) and not always associates
with clinical cardiac amyloidosis [31].
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2. Specific features of cardiac amyloidosis
2.1. Pathology
Grossly, amyloid can be seen to infiltrate any or all cardiac structures including the myocar‐
dium (atrial and ventricular), valves, conduction system, coronary and large arteries [32]. This
usually results in thickening of all 4 chambers, biatrial dilatation, normal or mildly dilated
right ventricle and normal or small left ventricular cavity. The conduction system is usually
involved. Valve infiltration may lead to thickening or nodule formation. Valve regurgitation
is generally mild but can be severe.
Microscopically, myocardial cells separate and are distorted by amyloid deposition [33].
Amyloid deposits stain pink with Hematoxylin and Eosin and show an apple-green birefrin‐
gence when stained with Congo red and viewed under polarized light. By electron microscope
the fibrils are non-branching with a consistent diameter of 7.5 to 10 nm [34]. Additionally, the
intramyocardial vessels are frequently infiltrated by amyloid [34]. Rarely this small vessel
involvement will cause the initial presentation with only minimal myocardial infiltration.
Involvement of epicardial vessels is rare but may mimic atherosclerotic plaques. There may
be differences in patterns of deposition between AL and SSA amyloid to suggest more vascular
involvement in the former [35].
2.2. Clinical manifestations
In AL amyloidosis, cardiac manifestations are rare to occur without associated systemic
manifestations such as gastrointestinal symptoms or heavy proteinuria [36]. Age at presenta‐
tion is typically in the fifth to sixth decade, and is rare in patients younger than 30 [36]. ATTR
may present with or without neurologic manifestations. SSA usually does not involve other
organs, with the exception of carpal tunnel symptom and will manifest usually in an older
patient.
Heart failure is the usual cardiac manifestation, typically with preserved left ventricular
ejection fraction. Biventricular failure is usually present, but the presenting symptoms are often
those of right heart failure including ascites and peripheral edema. This can help differentiate
from cardiac hypertrophy due to hypertension alone, where right heart failure is less common
on presentation. Other non specific symptoms include fatigue and orthostatic hypotension.
Due to the high prevalence of ATTR in the African American population, symptoms of right
heart failure in an African American in his/her sixth decade with ventricular wall thickening
should alert the physician to suspect familial amyloidosis (transthyretin, Val Ile122) rather
than hypertensive heart.
Other cardiac manifestations include arrhythmias and dysrhythmias. Atrial fibrillation is
common and may worsen heart failure symptoms. Possible causes of atrial fibrillation are atrial
infiltration, elevated left atrial pressure due to the diastolic dysfunction and older age (in SSA
amyloidosis). Syncope and sudden death can occur. Differential diagnosis includes orthosta‐
tism and arrhythmias. Arrhythmias can include brady-arrhythmias such as caused by
conduction delays. Ventricular tachy-arrhythmias are described but sustained VT is uncom‐
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mon and most cases of monitored sudden death were due to electro-mechanical dissociation
[37]. Chest pain due to small vessel disease is a rare (1-2%) presentation of AL amyloidosis [38].
In some of these cases imaging studies may be positive but coronary angiography will
demonstrate normal epicardial vessels.
Another clinical aspect is the tendency for thromboembolic events. As stated above atrial
fibrillation is a common finding, especially with advanced disease. Atrial standstill can occur
due to amyloid infiltration even in the presence of sinus rhythm and contribute to thrombus
formation. In AL amyloid nephrotic syndrome can also contribute to hypercoagulopathy and
thrombus formation. Although debated, these risks may warrant a relatively liberal use of
anticoagulation as discussed below [39]-[41] [42].
2.3. Diagnosis
The diagnosis of cardiac amyloidosis can be challenging. A high level of suspicion is needed
since diagnosis can often be missed, especially with the transthyretin amyloidosis. Patients
may be misdiagnosed with more common causes of heart failure associated with cardiac
hypertrophy such as hypertensive cardiomyopathy. Clinical suspicion usually arises during
evaluation for right sided heart failure, because other manifestations of cardiac amyloidosis
occur less commonly. Systemic manifestations typical of each type of cardiac amyloidosis may
be supportive of the diagnosis. Further basic evaluation includes electrocardiography and
echocardiography. More advanced evaluation including MRI and radioisotope and hemody‐
namic studies may also be utilized to substantiate the diagnosis. Definite diagnosis is generally
made by cardiac biopsy and pathological evaluation but may not be needed in every case.
2.4. Cardiovascular directed physical examination
An irregular rhythm due to atrial fibrillation occurs in 10-15% of the patients. Blood pressure
is often low and can further decrease with standing. Manifestations of right heart failure due
to restrictive cardiomyopathy will include an elevated jugular venous pressure but Kussmaul’s
sign is rarely present (in contrast to constrictive pericarditis). The apex beat is frequently
impalpable. The first and second heart sounds are usually normal. A left ventricular S3 is rare
but a right ventricular S3 may be heard. A fourth heart sound is almost never present, possibly
due to atrial dysfunction [9]. On chest examination rales are uncommon but pleural effusion
may occur both due to heart failure as well as to amyloid involvement [43]. Hepatomegaly is
common, due to either congestion or AL amyloid infiltration (causing a rock-hard organ in the
latter case). Peripheral edema may be profound, especially if nephrosis co-exists.
2.5. Systemic findings
The diagnosis of systemic amyloid involvement and findings of monoclonal immunoglobulin
light chain may suggest AL amyloidosis. In detecting serum light chain, immunofixation is
preferred to electrophoresis since the amount of paraprotein may be small. Serum free light
chain assay is even more sensitive than immunofixation [44]. The finding of a monoclonal
protein is not necessarily pathological and differential diagnosis includes monoclonal gamm‐
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opathy of uncertain significance (MGUS). A monoclonal protein as an incidental finding
(MGUS) can be found in up to 5-10% of patients more than 70 years old [45]. Not all cases are
benign and the quantitative serum free light chain assay may predict progression in some cases
[46]. The combination of abnormal kappa/lambda ratio and positive immunofixation identified
99% of patients with AL amyloidosis [47]. When considering the serum immunoglobulin free
light chain, elevations of either the serum kappa or lambda free light chain in the context of a
normal ratio between the two does not suggest a clonal process, like what one sees in AL. Renal
failure and non-specific inflammation can cause elevation of both types of light chain, and the
normal ratio is preserved. Light chain elevations associated with a clonal process will also
include an abnormal ratio. Amyloid deposition can be found in abdominal fat needle aspiration
and used for tissue confirmation of systemic amyloidosis [48],[49]. Eventually bone marrow
biopsy is necessary to assess the percentage of plasma cells and rule out myeloma and other
disorders such as Waldenstrom’s macroglobulnemia.
In the case of ATTR amyloidosis systemic evaluation should focus on a thorough neurological
evaluation including eye examination. Genetic analysis may be helpful if ATTR is suspected,
especially if a familial trait is identified and may be utilized in consulting siblings.
2.6. Electrocardiography
Low voltage  QRS (<5mm in  all  limb leads)  [50]  is  one  of  the  hallmarks  of  the  disease.
However the lack of low voltage does not rule out the disease and in very rare cases, an
unusual presentation with EKG features of left  ventricular hypertrophy has been descri‐
bed. Other common observations include pseudoinfarct pattern, repolarization alterations
and T-wave abnormalities, and atrial fibrillation [51]. Atrial involvement may lead to de‐
layed atrial  conduction and a long PR interval.  Interestingly,  bundle branch blocks tend
to be uncommon [9]
2.7. Echocardiography
Usually ventricular wall thickening in the absence of left ventricular cavity dilatation is seen.
Ejection fraction is often normal. Trans-mitral Doppler and tissue Doppler frequently suggests
elevated left ventricular filling pressure [52],[53]. A decreased transmitral A wave can be due
to the direct effect of atrial infiltration and not only the restrictive physiology therefore a
normal E wave deceleration time with small A wave can be encountered [54] [55]. Pericardial
effusion is common. A typical echocardiographic image is shown in figure 1.
Clues to differentiate LV thickening due to amyloidosis from LV hypertrophy include:
1. Disproportional impairment of longitudinal motion. Subendocardial fibers are particu‐
larly susceptible to damage in amyloidosis. Since these are longitudinal, the longitudinal
contraction of the heart is impaired early in the disease process. This can be diagnosed
using tissue Doppler as well as strain and strain rate [56],[57].
2. Involvement of other cardiac structures including RV free wall thickening, prominent
biatrial dilatation and valvular thickening.
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3. Absence of high voltage QRS on surface EKG despite the appearance of a thickened
left ventricle. The opposite may occur with decreased voltage as ventricular mass is
increased [58].
In about 5% of patients cardiac amyloidosis can mimic hypertrophic cardiomyopathy echo‐
cardiographically [59],[60]. Unlike true hypertrophic cardiomyopathy ventricular hypertro‐
phy on the EKG limb leads is almost never seen and systolic anterior motion of the mitral leaflet
is uncommon, although chordal anterior motion may be present.
Echocardiographically distinguishing the different types of cardiac amyloidosis is challenging.
Ventricular cavity is usually smaller and ventricular walls thicker in SSR compared to AL
amyloidosis [61]. One clue to differentiate ATTR and AL amyloidosis may be that QRS voltage
may be higher due to the amount of ventricular thickening in ATTR as compared to AL
amyloidosis [62]. Subtle differences in strain and strain rate were described between the two
[57]. These are possibly related to the toxic effects of the light chains in AL, absent in ATTR
amyloidosis [12].
2.8. Magnetic Resonance Imaging (MRI)
Gadolinium tends to accumulate in the amyloid infiltrated cardiac interstitium. Therefore a
distinctive pattern in cardiac MRI can be highly suggestive of the diagnosis. This consists of
faster washout than usual from blood and myocardium, and later a diffuse, predominantly
subendocardial delayed gadolinium uptake pattern [63]-[68]. A representative MRI is shown
in figure 2. Less commonly a focal distribution with variable trans-mural extension is seen,
more often in the mid-ventricle [69]. The analysis of gadolinium kinetics may have prognostic
Figure 1. Representative echocardiographic image in a patient with cardiac amyloidosis. Parasternal long axis
echocardiographic view showing granular myocardium with increased left and right ventricular wall thickness in a 77
year old with cardiac amyloidosis. Note the pericardial effusion.
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value as well as diagnostic utility [70]. The use of gadolinium may be restricted by the potential
harm of causing nephrogenic systemic fibrosis in patients with renal impairment (especially
in AL amyloidosis) and therefore the possible utility in substantiating the diagnosis should be
carefully weighed against this possible risk.
Figure 2. Magnetic resonance image in cardiac amyloidosis. Cardiac MRI showing a short axis myocardial delayed
enhancement image obtained 10 minutes following gadolinium administration demonstrating diffuse abnormal en‐
hancement (white) of the right ventricular free and inferior walls as well as focal abnormal enhancement of the in‐
ferolateral left ventricular myocardium in a subendocardial distribution. The diffuse abnormal enhancement involving
both right and left ventricles is characteristic of cardiac amyloid deposition.
2.9. Radioisotope imaging
Serum amyloid P binds in a calcium dependent way to amyloid and 123I-labeled serum
amyloid P component has been used to identify amyloid deposits. However its use in the heart
is hampered by blood pool uptake [71] and it is available only in a few highly specialized
centers. 99m-Tc-aprotinin may be fairly specific for cardiac amyloidosis but experience with
this tecnique is limited [72].
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2.10. Hemodynamics
Amyloid cardiomyopathy physiology is typically restrictive. Left ventricular end diastolic
pressure (LVEDP) is typically elevated with a dip and plateau waveform. Since the left
ventricle does not dilate the patients are usually sensitive to volume loading and even small
reductions in contractility may cause significant reduction in stroke volume. However
hemodynamics displayed by catheterization are not always typical. Among 38 patients with
ATTR cardiac amyloidosis one had an RV pressure curve dip and plateau, 34% had elevated
wedge pressure. Interestingly 29% patients did not display hemodynamic diastolic abnormal‐
ities at rest [73].
Differentiation from constrictive pericarditis may necessitate a simultaneous right and left
hemodynamics study. Early observations suggested that unlike constrictive pericarditis, in
amyloidosis LVEDP is elevated at least 7mmHg above right ventricular end diastolic pressure
[74]. Later reports have argued this is not always the case and amyloidosis can masquerade
constriction hemodynamics [75]. Pulmonary systolic pressure >50mmHg is another parameter
thought to be less likely in pure constriction and if occurs may suggest restrictive physiology
such that occurs with amyloidosis. Currently accepted parameters that best differentiate
constriction from restrictive cardiomyopathy include exacerbated interventricular depend‐
ence (demonstrated by increased inspiratory rise in RV pressure and fall in LV pressure as
measured by the systolic area index) and dissociation between intrathoracic and intracardiac
pressures [76] [77].
2.11. The role of cardiac biopsy
In treating a patient with suspected cardiac amyloidosis, the clinician may be faced with the
dilemma whether to perform a cardiac biopsy, most commonly in the setting of TTR. A careful
risk benefit evaluation is warranted for every case since, while this procedure may provide
useful diagnostic information [78],[79], the risks are not negligible. Myocardial biopsy has a
good negative predictive value (since cardiac involvement is widespread). Biopsy of the
myocardium (or any involved tissue) provides information on the type of amyloid. The most
accurate technique appears to be molecular analysis of the amyloid fibrils using mass spec‐
trometry [80]. In patients with a confirmed diagnosis of systemic amyloidosis via biopsy proof
of another tissue, ventricular wall thickening and low or normal voltage EKG, the diagnosis
of cardiac amyloidosis is probable and biopsy should be avoided. If the patient is hypertensive
and there is uncertainty regarding cardiac involvement, biopsy may be useful. The most
accessible tissue to biopsy is that abdominal fat, which has sensitivities for AL of about 80%
and for TTR of about 40%. If suspicion of amyloidosis is high, and there is no other organ
involvement, cardiac biopsy may be needed to confirm the diagnosis. Since small amounts of
amyloid deposition are a common finding in the very elderly [81] caution should be taken
when interpreting the results in this population, especially if the amyloid deposits are sparse
and the echocardiographic appearance is not convincing. In an elderly patient with clinical
and echocardiographic findings consistent of cardiac amyloidosis and free light chain in the
serum the differential will include coincidental SSA amyloid and MGUS versus AL amyloid.
If other tissue is not available or yields negative results, endomyocardial biopsy with typing
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using laser capture mass spectrometry or immunochemistry or immunogold electron micro‐
scopy may be needed to differentiate ATTR from AL.
2.12. Prognostic markers
The type of amyloidosis by itself is an important determinant of survival and every type should
be considered separately when discussing prognostic issues. Patients with AL amyloidosis
generally carry the worst prognosis and most of the current research on prognostic evaluation
is focused on this group. Clinical features such as low ejection fraction and low voltage pattern
were associated with increased mortality [82]. Cardiac biomarkers may be elevated in patients
with AL and are being utilized to estimate prognosis. Cardiac troponins may be elevated due
to myocyte death or injury and elevated levels predict worse prognosis in AL patients [83].
Elevated brain natriuretic peptide (BNP) may reflect both congestive HF as well as compres‐
sion by adjacent amyloid deposits [84],[85] and has also been associated with worse survival.
Staging using serum levels of BNP or its n-terminal portion (NT-proBNP) together with serum
troponin is used to aid in risk assessment and prognosis in AL amyloidosis [86],[87]. More
recently, a risk stratification score using cardiac troponin, NT-proBNP and uric acid was
developed to assess early death among AL patients [88]. Even more recently, an additional
risk score that includes NT-proBNP, troponin T, and serum immunoglobulin free light chain
adds further prognostic discrimination[89].
2.13. Prognosis
In the absence of treatment, the natural history of AL amyloidosis is dismal (80% two year
mortality) [90]. Although prognosis has improved over the years with the advancement of
treatment [88], mortality remains high, especially in the presence of heart failure symptoms
(median survival 4-6 months) [11]. The course in ATTR amyloidosis is generally more indolent,
with 92% 1 year survival [62] and heart failure may be easier to control. Genotypes differ in
prognosis, and patients with the Val30Met mutation tend for better prognosis compared to
other mutations [24]. Senile amyloidosis is also associated with better survival compared to
AL amyloidosis, despite older age of presentation and thicker myocardium by echocardiog‐
raphy [61]. In one report median survival was 60 months, compared to 5.4 months for AL
amyloidosis [91]. Similar results were shown in a larger series comparing the 3 major cardiac
amyloidosis syndromes [73].
3. Treatment
3.1. Disease specific treatment
Cardiac dysfunction in AL amyloidosis may be caused by direct toxicity of the circulating
serum free light chains, in addition to the deposited amyloid tissue [13]. Therefore, treatment
of the underlying plasma cell dyscrasia in AL amyloid involving chemotherapy [92] can cause
a reduction in the cardiac biomarker NT-proBNP and improve survival [14],[93]. A range of
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chemotherapies ranging from low dose melphalan and dexamethasone to high dose melpha‐
lan with autologous hematopoietic stem cell transplantation are among the most commonly
used therapies. One of the more promising, but least well studied drugs, that is directed against
the plasma cell clone is bortezomib. Bortezomib is a proteasome inhibitor and utilizing it, a
hematological response can be achieved more rapidly (in about a month) in high percentages
of patients [94],[95], but clinical trials using this drug have typically excluded those AL patients
with the most significant cardiac dysfunction. Other treatments using thalidomide or lenali‐
domide may also be effective, but these drugs have been shown to exacerbate cardiac failure
in a percentage of patients [96]. Despite the advancement in hematological treatment, mortality
in patients with severe heart failure is still high [97]. Moreover, worsening of cardiac function
may occur during the course of treatment and an ejection fraction below 40% is considered a
contraindication to high dose chemotherapy with autologous hematopoietic stem cell trans‐
plantation. The complexity and potential deterioration of cardiac function during treatment
warrants cardiologist involvement during evaluation for chemotherapy and during follow-up
after treatment in every case, even if cardiac involvement seems minor.
Stabilization of the tetrameric structure of transthyretin using small molecule ligands is under
investigation [98] and may assist patients with TTR associated amyloidosis. The non-steroidal
anti-inflammatory drug Diflunisal has been found to have this effect [99],[100] but chronic use
is limited due to possible worsening of fluid overload and renal function. Tafamidis is a novel
transthyretin kinetic stabilizer which has been recently investigated clinically [101]. In a
randomized trial this agent was well tolerated and showed a trend for delaying peripheral
neurologic impairment in patients with ATTR [102]. While showing promise, this agent is not
yet in routine clinical use.
3.2. Conventional heart failure treatment
It is important to differentiate AL from ATTR amyloid. While in AL amyloid “conventional”
heart failure treatment including beta blockers and angiotensin pathway inhibitors is usually
not well tolerated, these medications may be better tolerated in ATTR patients who do not
suffer from significant autonomic neuropathy. Calcium channel blockers with negative
inotropic effects have no role in AL amyloid and may cause harm [103] [104]. Compared to
other causes of heart failure there is no evidence for remodeling effects from beta blockers and
therefore they are not indicated for patients in sinus rhythm [105]. They may be used to slow
atrial fibrillation response if needed, but take care if your patient decompensates after
institution. Amiodarone and digoxin may be preferred for rate control. Due to their impaired
cardiac function (and restrictive LV filling), some of these patients require mild tachycardia to
maintain cardiac output. There is also no role for digoxin for patients in sinus rhythm but it
also may help slow atrial fibrillation response. Possible increased toxicity by increased binding
of digoxin to amyloid fibrils has been reported [106] and therefore lower dosing and caution
is probably justified when using this medication. Angiotensin pathway inhibitors (both
angiotensin converting enzyme inhibitors and receptor blockers) may provoke hypotension
(possibly due to impaired sympathetic nervous system function and reduced and relatively
fixed stroke volume) and therefore should be administered only if being used to treat hyper‐
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tension [32]. Patients with SSA amyloid tend to tolerate these medications better than patients
with AL amyloid. Diuretics and salt restriction remains the mainstay of medical treatment in
cardiac amyloidosis. Careful titration is utilized since reduced preload with reduced ventric‐
ular filling pressures can decrease cardiac output and cause hypotension. Higher doses may
be needed if albumin is low as a result of nephrotic syndrome (with AL). If absorption is
impaired due to anasarca, intravenous treatment may be necessary sometimes in association
with IV albumin.
Ancillary treatment in patients with autonomic neuropathy includes compression stockings
and alpha adrenergic agonists such as midodrine [107]. Fludrocortisone is usually less well
tolerated due to its sodium retaining effects and worsening of edema. Patients with erectile
dysfunction can be aided by phosphodiasterase inhibitors [108].
The question of anticoagulation is complex since both a thrombotic tendency as well as a
bleeding tendency (especially in AL) may occur. ATTR patients tend to bleed less than AL
patients. Due to an increased risk, anticoagulation with warfarin is probably indicated when
atrial fibrillation occurs, even in the absence of other risk factors. The decision is more complex
in patients with sinus rhythm. Because of an increased tendency for thrombotic events and the
occurrence of atrial stand-still, anticoagulation should be considered. Though this must be
counterbalanced by the increased risk of bleeding, especially from the GI tract. The head and
neck purpura may also be a challenge to manage among patients on anticoagulation. Atrial
thrombi were indeed identified in patients with AL amyloid in sinus rhythm [39]. A small
transmitral A wave (<20cm/s) can suggest impaired atrial function with more tendency to form
thrombi and can be used as another clue to decision making. Transesophageal echocardiog‐
raphy may help to identify patients in sinus rhythm with higher risk for thrombosis such as
those with spontaneous echo contrast or low left atrial appendage velocities. A cutoff of <40cm/
sec was initially suggested [109] but this may be considerably lower (reported as 13±5cm/sec
for patients with and 27±15cm/sec for patients without thrombosis) [41].
3.3. Arrhythmia, pacing and defibrillators
Maintenance of sinus rhythm seems important in the stiff restrictive amyloidotic hearts,
possibly due to the importance of the atrial kick and avoiding tachycardia. Therefore careful
consideration should be given to electrical cardioversion for atrial flutter or fibrillation.
Amiodarone can be useful to help maintain sinus rhythm. If pacing is needed strong consid‐
eration should be given to biventricular pacing since RV pacing and the resulting dysynergy
may decrease stroke volume.
Sudden death is common in patients with cardiac amyloidosis. Early studies using holter
monitoring suggested a high incidence of ventricular arrhythmia [110]. However, it is
presently thought that the cause of death is less often rapid ventricular arrhythmias but may
include electromechanical dissociation [111] and advanced heart block. Among 19 patients
with either non-sustained ventricular tachycardia or high grade ventricular arrhythmia treated
with an ICD only 2 received appropriate shocks for sustained VT, while 6 died of electrome‐
chanical dissociation [112]. Thus, there seems to be little role for implantable pacemakers in
cardiac amyloid patients, unless a sustained ventricular arrhythmia was documented.
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Amiodarone has been used to try and prevent arrhythmias and sudden death although there
is no clear evidence of benefit.
4. Advanced heart failure treatment
4.1. Cardiac transplantation in AL amyloidosis
The negative impact of cardiac involvement on survival, the rapidly deteriorating clinical
manifestations and the potential for hematologic treatment led clinicians as early as the 1980’s
to consider cardiac transplantation in AL amyloid. While initial reports based on individual
cases generated optimism [113],[114], subsequent experience highlighted suboptimal out‐
comes [115] calling for careful and specialized patient selection and management, including
disease modifying hematological treatment such as bone marrow transplant. In selected
patients with both cardiac and renal failure, combined heart kidney transplant may be offered
[116]. All these considerations necessitate that transplant for this complex population is carried
out in highly specialized centers with high volumes.
4.2. Patient selection
Patient selection for patients with cardiac amyloidosis is usually a complex decision that is to
be based on careful evaluation involving multiple disciplines. Considerations include the
routine assessment utilized in “ordinary” cardiac transplant including factors such as age,
frailty, the advancement of cardiomyopathy and co-morbidities. Additional evaluation
specific to the AL includes evaluating whether other organs are involved, ruling out multiple
myeloma, and collaboration with a hematologist regarding chemotherapy. Baseline evaluation
before considering heart transplant includes therefore bone marrow aspirate and biopsy,
echocardiogram, serum and 24-hour urine monoclonal protein studies, serum immunoglobu‐
lin free light chain assay, a chemistry panel including creatinine, liver function tests and renal
clearance estimates (table 1). Major involvement of other organ systems will render the patients
as less optimal candidates. This includes evidence of peripheral neuropathy, autonomic
neuropathy, gastrointestinal symptoms (diarrhea), hepatic involvement, and renal failure.
Patients with significant proteinuria (>500 mg/day) are usually considered higher risk due to
kidney involvement. Hepatic involvement may be suspected with elevated alkaline phospha‐
tase and hepatomegaly and a liver biopsy may be needed to differentiate it from right heart
failure. Since amyloidosis is a vascular disease, the mere presence of vascular involvement in
the liver would not render a patient ineligible for cardiac transplant. The acronym DANGER
was suggested for evaluation of tissue involvement and adverse outcome in the context of pre-
transplant evaluation for AL amyloid. It includes Diarrhea, Autonomic nervous involvement,
poor Nutritional status, Gastrointestinal involvement (bleeding), Elimination (renal) or Respirato‐
ry dysfunction[117]. Recurrent pleural effusion (more common in AL amyloidosis) is also an
ominous sign for bad prognosis [43].
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Routine cardiac transplantation
evaluation with the following
additional studies:
• Serum protein electrophoresis
• Urine protein electrophoresis (24-hour urine)
• Factor X and thrombin time (special coagulation studies)
• Bone marrow biopsy with aspirate, labeling index and smear
• Labeling index in peripheral blood with number of circulating plasma cells
• Serum carotene
• β2-microglobulin
• C-reactive protein
• 24-hour urine creatinine clearance
• 48-hour stool collection for fat
• Subcutaneous fat aspirate
• Metastatic bone survey with single views of humeri and femurs
Pulmonary assessment will proceed as
follows:
Recurrent pleural effusions, refractory to treatment will necessitate:
• Chest CT
• Possible lung biopsy dependent on CT findings
Liver assessment will proceed as
follows:
• If alkaline phosphatase <1.5-fold upper limit of normal (350), then proceed
with transplant evaluation
• If alkaline phosphatase 1.5- to 3-fold upper limit of normal, then proceed to
liver biopsy:
1. If there is portal tract amyloid deposition, then there is an absolute
contraindication
2. If vascular amyloid only, then proceed with transplant evaluation
• If alkaline phosphatase is ≥3.0-fold upper limit of normal (750), absolute then
there is an contraindication to HT
Renal assessment will proceed as
follows:
Lothalamate clearance should exceed 50 ml/min/1.73 m2
• If urinary albumin is <250 mg/24 hours, then proceed with transplant
evaluation
• If urinary albumin is 250 to 1,000 mg/24 hours, then proceed to renal biopsy
1. If vascular amyloid only, is present then proceed with transplant evaluation
2. If interstitial or glomerular amyloid is present, then there is an absolute
contraindication to cardiac transplant
Blood/marrow plasma cell labeling
index assessment will proceed as
follows:
Plasma cell labeling index
• If plasma cell labeling index is ≥2%, then exclude from consideration for
transplant evaluation
• If plasma cell labeling index is ≥1%, then proceed to metastatic bone survey
to exclude myeloma-associated bony lesions
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• If plasma cell labeling index is <1%, then proceed with transplant evaluation
Peripheral blood labeling index
• If peripheral blood plasma cell labeling index is "/>1%, then absolute
contraindication to cardiac transplant
Plasmacytosis
• If plasma cell differential on marrow aspirate is <10%, then proceed with
transplant evaluation
• If plasma cell differential on marrow aspirate is 10% to 20%, then do
metastatic bone survey to exclude myeloma-associated bony lesions
• If plasma cell differential on marrow aspirate, marrow biopsy or cytoplasmic
immunoglobulin–positive plasma cells are ≥20%, then contraindication to
there is an absolute cardiac transplant
Intestinal assessment will proceed as
follows:
• 48-hour stool collection for fecal fat to rule out malabsorption
• Serum carotene if low level could indicate malabsorption
• Endoscopic and flexible sigmoidoscopic evaluation with biopsy
1. If vascular amyloid deposition only, then proceed with transplant evaluation
2. If mucosal amyloid deposition, then there is an absolute contraindication to
cardiac transplantation
Adopted from Lacy MQ et al. 2008.
Table 1. Pre-transplant evaluation of AL amyloid patients.
4.3. High dose chemotherapy with autologous hematopoietic stem cell transplant (ASCT)
after heart transplant in patients with AL
Since the clinical course of these patients is usually rapidly progressive once heart failure
occurs, death rates on the transplant list tend to be high. Cardiac transplant alone does not halt
the ongoing amyloid deposition and although it results in temporary improvement, this is
followed by an overall poor prognosis [114],[115]. Unless therapy directed at the underlying
plasma cell clone is effective, the amyloid may also recur in the transplanted heart at a later
stage, despite initial clinical improvement of heart failure [118]. Therefore, the treatment
strategy should be to follow the heart transplant with chemotherapy, usually within 6 months
to a year after the heart transplant to allow for healing from the surgery and tapering down of
the immunosuppression. Initial experience was described in 5 patients, of whom 2 died of
progressive amyloid and 3 survived [119]. With increasing experience with patient selection
and treatment results are improving [120] and in selected patients prognosis may be compa‐
rable to non-amyloid patients [117]. This strategy has been shown to be feasible and associated
with improved survival with carefully selected patients [121]. Although there are some reports
of late recurrence of cardiac amyloidosis [122] despite ASCT this is considered still the strategy
that offers the best chance for long term good outcomes.
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Since the disease is rapidly progressive and patients will generally wait 4-6 months after heart
transplant to be fit for ASCT. Therefore timing of heart transplant is especially crucial in this
patient setting since patients might miss the window of opportunity for hematologic treatment.
Extended donor criteria have been advocated and may be utilized to facilitate a timely
transplant in selected cases [123]. Another approach would be to consider heart transplant
after successful hematological treatment including ASCT [124], but this strategy is fraught with
more hazard, because of the high risk of death among ASCT AL patients with cardiac amyloid
bad enough to require cardiac transplantation.. Newer chemotherapeutic agents that are better
tolerated may be used to achieve partial remission [95] and may halt the progression of cardiac
symptoms by decreasing serum levels of light chains with potential toxic myocardial effects,
and thereby facilitate survival on the waiting list for heart transplant.
4.4. Outcomes of heart transplant in AL cardiac amyloidosis
Survival in transplanted patients with amyloidosis is generally poorer when compared to
patients without amyloidosis. Five year survival rates reported from the European registry
were 38%, with prevalent progression of the systemic disease [125]. Analyzing results of the
United Network of Organ Sharing for 69 patients with amyloid heart disease, 1 year actuarial
survival was 74.6% compared to 81.6% for all other heart transplanted patients and 5 year
survival was 54% versus 63.3% respectively. The authors included all types of amyloid and
did not detail treatment for the underlying disease [126]. Data from other registries suggests
poorer prognosis for patients transplanted with AL amyloidosis compared to other types of
cardiac amyloidosis [127]. As described above, survival may be improved if bone marrow
transplantation is performed after cardiac transplant. In carefully selected patients survival
utilizing this strategy can reach about 60% in five years which is comparable to the general
heart transplant population [121],[128],[129].
4.5. Cardiac transplantation for transthyretin related amyloidosis
Heart transplant for significant cardiomyopathy related to transthyretin amyloid deposition
has been successfully deployed with overall good outcomes. Specific considerations include
possible associated neuropathy and need for combined heart-liver transplant in ATTR
amyloidosis and the advanced age of presentation in SSA amyloidosis.
4.6. Patient selection
In ATTR cardiac amyloidosis a major determinant of pre-transplant evaluation and candidacy
is the presence and severity of associated neuropathy. Autonomic disturbances should be
evaluated specifically including orthostatic hypotension, gastrointestinal and urinary tract
dysfunction. Other factors of importance include the body mass index, patient age and degree
of disability. Generally patients with SSA are not offered transplant due to their advanced age,
however if presenting early, transplantation may be successfully performed [130].
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4.7. Combined heart and liver transplant in ATTR cardiac amyloidosis
Since the abnormal transthyretin is primarily synthesized by the liver, liver transplantation is
a reasonable treatment for ATTR. Liver transplantation in ATTR can halt, and in some cases
is associated with regression of amyloid deposits [131],[132]. This is especially true for certain
mutations (such as Val30Met) where liver transplantation can halt neurological symptoms and
improve general symptoms (gastrointestinal, nutritional, orthostasis and dyshidrosis)
however this mutation less commonly causes cardiac disease [132]. Paradoxical acceleration
of cardiac involvement after liver transplantation may occur in patients with mutation variants
other than Val30Met [133]-[135], due to wild-type transthyretin deposition in addition to the
background amyloid fibrils [136]-[138]. Therefore combined heart and liver transplantation
rather heart transplant alone is considered in patients with significant cardiac involvement
[139],[140]. Combined heart and liver transplantation can be performed in selected patients
with results similar to heart transplant for other indications [141]. The indications for combined
heart liver transplant include patients with heart failure symptoms and without advanced
neurological involvement and patients with non Val30Met mutations who are candidates for
liver transplant and have echocardiographic evidence of cardiomyopathy.
The liver in these patients otherwise functions normally and generally the explanted liver can
be used for another patient requiring liver transplantation (domino transplant) [142]. Amyloid
deposition from the implanted liver is thought to occur very slowly. Rare cases of recurrence
of amyloid deposition in the liver recipient have been reported 8-10 years after the transplant
[143]-[145].
The surgical approach to combined heart-liver transplant has changed over the years. Ini‐
tially  transplantation of  the  heart  and maintaining the  patient  on cardio-pulmonary by‐
pass  during  the  liver  transplant  was  used.  Subsequent  concerns  about  substantial
coagulopathy and increased bleeding changed the strategy to performing liver implanta‐
tion after separation from cardiopulmonary bypass [139],[146],[147]. Later, improved sur‐
gical  and anesthetic  techniques  during liver  transplant  and the  potential  benefits  to  the
transplanted heart  to  remain on cardio-pulmonary bypass  during liver  implantation led
to revising this  strategy.  This  technique was suggested to provide a considerably short‐
ened liver ischemia time and decreased blood transfusion compared to the sequential ap‐
proach  [148].  Staged  heart  and  liver  transplantation  where  initial  cardiac  transplant  is
later followed by liver transplant from a different donor can be used,  especially for pa‐
tients  that  are  hemodynamically  unstable  after  cardiac  reperfusion  [149],[150].  However
the preferred method is a single donor transplant, due to the avoidance of a second ma‐
jor operation early after cardiac transplant as well as certain possible immunological ad‐
vantages.  In  cases  of  elevated  pre-formed  anti-HLA  antibodies,  there  might  be  an
advantage to a surgical strategy where liver transplant is performed initially, followed by
sequential  heart  transplant.  The liver  is  thought  to  sequester  pre-formed anti-HLA anti‐
bodies and “protect” the heart in this scenario. This approach necessitates maximal coor‐
dination to avoid a prolonged ischemic time for the implanted heart but was successful
at least in one case [151].
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Interestingly, heart rejection is infrequent in combined heart-liver compared to heart alone
transplantation [141]. A possible explanation may be an induction of partial tolerance. The
liver has been demonstrated to shed soluble HLA antigens [152],[153]. Soluble HLA antigens
may lead to tolerance of the specific allotype and permit acceptance of other transplanted
organs [154]. Less intensive immunosuppression may be needed in these cases and a reduced
tendency for allograft vasculopathy has been recently demonstrated [155]. Overall, potentially
due to the supportive contribution of these considerations and despite a larger and more
complex operation results for the heart and liver transplant are comparable to those in other
heart transplant patients [125].
4.8. Cardiac assist devices in patients with cardiac amyloidosis
Left ventricular assist devices (LVAD) are currently implanted for patients with advanced
heart failure and improve survival and quality of life. The number of devices implanted and
medical centers involved in device implantation is rapidly increasing and newer continuous
flow devices replacing the older pulsatile ones and allowing for improved durability [156].
While traditional indications for LVAD support were dilated cardiomyopathies (either
ischemic or non-ischemic), LVAD implantation has been successfully administered to patients
with primarily restrictive physiology. Early reports of include implantation and successful
support for one patient with amyloidosis with the Jarvik-2000 device [157]. A case series
recently described successful support with the HeartMate II device in patients with restrictive
cardiomyopathy, several of whom had cardiac amyloidosis [158]. Candidates had transthyr‐
etin related cardiac amyloidosis since the immune suppression, coagulopathy and systemic
involvement in AL amyloidosis renders them less optimal candidates for this line of treatment.
In selecting patients with cardiac amyloidosis for LVAD some important considerations
should be considered. Since the assist device will not support the right ventricle, specific
consideration should be given to assess the right ventricular function. Detailed directed
echocardiographic evaluation as well as hemodynamic catheterization are critical to estab‐
lishing candidacy. The right ventricle is anticipated to be involved in the infiltrative disease
and RV dilatation may not occur despite significant dysfunction. Total artificial heart implant
may be considered if right ventricular function is poor suggesting that LVAD support alone
may not be sufficient. However the long-term durability of these devices has not been
evaluated and therefore implantation in patients not eligible for heart transplant (such as for
older patients with SSA) may be problematic. Another important consideration is the degree
of systemic involvement, particularly neuropathy. This will influence considerably their ability
to recuperate from the operation and the remaining degree of physical limitation and dys‐
function. Patients with LVAD support often display orthostatism and this may worsen if the
patient had pre-existing autonomic dysfunction due to amyloid. Overall, with careful patient
selection, meticulous operative technique (with extra care for cannula positioning in the small
cavity) and dedicated post-operative follow-up, assist devices can be deployed in patients with
cardiac amyloidosis with success rates comparable to conventional indications [158].
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